Pure-play consumer health company Kenvue Inc (NYSE:KVUE) reported first-quarter sales of $3.89 billion, beating the consensus of $3.79 billion. Kenvue’s some of the iconic brands include Aveeno, ...

(Reuters) -Kenvue forecast full-year profit below analysts' expectations after missing quarterly sales estimates on Thursday, as the Tylenol maker faces sluggish demand in China and slowing growth for ...

May 7 (Reuters) - Kenvue (KVUE.N), opens new tab will cut 4% of its global workforce amid investments to grow its key brands, the Tylenol and Band-Aid maker said on Tuesday, as it topped beat Wall ...

Michael Bromberg is a finance editor with a decade of experience. He is an expert at elucidating complex financial topics in clear, concise language. Michael received a Bachelor of Arts in literature ...

Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a massive consumer health goods company. Shareholders of Kimberly-Clark will own about 54% of ...

Tylenol, Listerine, and Band-Aid maker Kenvue is the latest in the health-related sector to attract an activist investor.

Kenvue targets annualized pre-tax gross cost savings of around $350 million by 2026 after workforce reduction of 4%. Kenvue expects the full year 2024 reported net ...